MindMaze Therapeutics outlines plan to top CHF 200 million annual revenue by 2031 in investor deck

(AWP Alliance News) - MindMaze Therapeutics Holding SA outlined plans to scale its neurorehabilitation platform from hospital to home, targeting more than CHF 200 million in annual revenue potential within five years. The group reported H1 2026 revenue of CHF 0.5 million, cash of CHF 6.3 million at June 30, 2026, annualized operating expenses of about CHF 12 million, no financial debt, and a CHF 4 million financing commitment.

It highlighted U.S. commercialization momentum, citing engagement with most of the top 20 U.S. stroke rehabilitation providers and deployments across about 100 hospitals and neurorehabilitation facilities. The presentation flagged a home-focused product expansion, with MindMotion Lite launch expected by year-end 2026, alongside a pharmaceutical distribution launch targeted for Q4 2026. MindMaze also pointed to longer-term upside from its AI and data platform, built on a continuously updated data lake and 1.2 billion validated deterministic expert algorithms.

https://docs.publicnow.com/BAE062C515453C4013E9CB9BD108E6F1C9AE67F6

Disclaimer: This news brief was created using generative artificial intelligence. MindMaze Therapeutics Holding SA published the original content used to generate this news brief on September 18, 2026, and is solely responsible for the information contained therein.